Trial Profile
A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Chronic lymphocytic leukaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Focus Therapeutic Use
- 14 Mar 2022 Status changed from active, no longer recruiting to completed.
- 22 Sep 2021 Planned End Date changed from 14 Aug 2020 to 1 Aug 2022.
- 22 Sep 2021 Planned primary completion date changed from 14 Aug 2020 to 1 Aug 2022.